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Abstract
An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert
panellists was convened on 15 January 2014 to review current evidence on the management of gallblad-
der carcinoma in order to establish practice guidelines. In summary, within high incidence areas, the
assessment of routine gallbladder specimens should include the microscopic evaluation of a minimum of
three sections and the cystic duct margin; specimens with dysplasia or proven cancer should be exten-
sively sampled. Provided the patient is medically fit for surgery, data support the resection of all gallblad-
der polyps of >1.0 cm in diameter and those with imaging evidence of vascular stalks. The minimum
staging evaluation of patients with suspected or proven gallbladder cancer includes contrasted cross-
sectional imaging and diagnostic laparoscopy. Adequate lymphadenectomy includes assessment of any
suspicious regional nodes, evaluation of the aortocaval nodal basin, and a goal recovery of at least six
nodes. Patients with confirmed metastases to N2 nodal stations do not benefit from radical resection and
should receive systemic and/or palliative treatments. Primary resection of patients with early T-stage
(T1b–2) disease should include en bloc resection of adjacent liver parenchyma. Patients with T1b, T2 or
T3 disease that is incidentally identified in a cholecystectomy specimen should undergo re-resection
unless this is contraindicated by advanced disease or poor performance status. Re-resection should
include complete portal lymphadenectomy and bile duct resection only when needed to achieve a nega-
tive margin (R0) resection. Patients with preoperatively staged T3 or T4 N1 disease should be considered
for clinical trials of neoadjuvant chemotherapy. Following R0 resection of T2–4 disease in N1 gallbladder
cancer, patients should be considered for adjuvant systemic chemotherapy and/or chemoradiotherapy.
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Pathologic evaluation of routine
cholecystectomy specimens and gallbladders
with neoplastic changes and polyps
Gallbladder carcinoma (GBC) is a rare malignancy, but in
selected areas of high incidence, such as India, Chile and
Japan, it is a significant source of mortality.1,2 Because of its
low incidence in most Western countries, GBC has been
understudied, leading to variation in approaches to the initial
pathologic evaluation, classification and staging of the disease.3
Protocol for routine pathologic assessment of
gallbladder specimens
Historically, pathologic under-sampling of gallbladder speci-
mens has led to under-diagnosis and under-staging. For those
patients in whom there is no clinical or imaging suspicion for
GBC and no apparent abnormality on gross examination,
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there is no consensus on a uniform pathologic examination
protocol. In many countries no microscopic examination is
recommended or performed in these situations.4 Given that
most cases of GBC are clinically unapparent on gross evalua-
tion, this implies that GBC may go undiagnosed in several
thousand cholecystectomies per year.5
To address this issue, a specific stepwise pathology sampling
protocol has been proposed.5,6 Particularly in areas of high
GBC prevalence, in gallbladders that appear normal on gross
examination, a minimum of three random areas and the cystic
duct margin should be submitted for microscopic assessment.
A finding of dysplasia or neoplasia on initial random sampling
prompts a complete sampling of the gallbladder. By contrast
with some reports,4 this practice is supported by data that
indicate that a significant number of patients initially found to
have dysplasia will harbour an invasive malignancy.6
High-risk features indicate the need for more
extensive routine sampling of the gallbladder
It has been established that certain disorders are associated
with GBC, including choledochal cysts, an anomalous union of
the pancreatobiliary ducts and primary sclerosing cholangitis.1
In such cases, a more thorough examination of the gallbladder
is warranted. More importantly, in cases with hyalinizing cho-
lecystitis, characterized by minimal to no calcifications
(‘incomplete porcelain gallbladder’), the incidence of subtle
invasive carcinoma appears to be very high and therefore these
cases ought to be thoroughly examined.7
Pathologic assessment of mass lesions of the
gallbladder
In gallbladder specimens with mass lesions suspicious for or
proven to be GBC, a complete analysis of the specimen is indi-
cated.5,6 Particularly in high-risk regions with frequent cases of
localized GBC, it is prognostically important to distinguish
early (muscle-confined) from advanced (through the tunica
muscularis) GBC.6 Data on longterm outcomes indicate that
when extensive and careful sampling confirms the absence of
advanced carcinoma, patients with early-stage GBC have a very
good prognosis (10-year survival of 90%).8–10 Additional path-
ologic prognostic factors that should be reported in cases of
confirmed GBC include involvement of Rokitansky–Aschoff
sinuses, multifocality of dysplasia, and involvement of the
hepatic versus free peritoneal surface of the gallbladder.8,9 The
determination of cystic duct margin involvement is potentially
important in subsequent surgical decision making. Thus, ade-
quate sampling to identify these prognostic findings is crucial
for proper staging and management protocols.
Pathologic evaluation of gallbladder polyps
Most polypoid masses of the gallbladder are small cholesterol
or fibromyoglandular lesions with no malignant potential.11
True papillary neoplasms (formerly referred to as adenomas)
do harbour a malignant potential, thought to be proportionate
to their overall size and degree of vascularity. In fact, gallblad-
der polyps of <1.0 cm in diameter seldom prove to be neoplas-
tic. By contrast, pathologic analyses suggest that most polyps
of >2.0 cm contain neoplasia. Although criteria for the thresh-
old polyp size that should indicate cholecystectomy are subject
to debate,12 there appears to be an increased incidence of
malignancy in polyps of >1.0 cm in diameter and in those with
a vascular pedicle,13–18 both of which are most commonly
determined with preoperative transcutaneous ultrasound exam-
ination with Doppler flow studies.
Classification of papillary gallbladder neoplasms
In a recent effort to align with the classification of papillary
tumours of the pancreaticobiliary tree, the category of intra-
cholecystic papillary tubular neoplasm (ICPTN) was created as
an umbrella term for all pre-invasive adenomatous polypoid
and papillary neoplasms of the gallbladder of >1.0 cm in
diameter.11 Regardless of the names assigned to these lesions,
all of these polypoid papillary lesions should be submitted for
microscopic examination. In cases of high-grade dysplasia in
the polyp, extensive sampling of the remaining gallbladder is
warranted because carcinomatous changes frequently occur in
the seemingly uninvolved portions.11
In summary, the systematic evaluation of all gallbladder
specimens in pathology laboratories is crucial for the accurate
diagnosis and staging of gallbladder neoplasms. For gallblad-
ders with dysplasia on initial evaluation and/or abnormalities
on gross examination, including hyalinizing cholecystitis and
suspicious gallbladder wall masses, extensive pathologic sam-
pling of the specimen is warranted. In preoperatively identified
polypoid lesions, a diameter of >1 cm and/or vascularity of the
stalk of the polyp represent indications for cholecystectomy.
Neoplastic polypoid/papillary lesions, proposed to be desig-
nated as ICPTNs, are highly analogous to their counterparts in
the pancreas [intraductal papillary mucinous neoplasms (IP-
MNs)] or bile ducts [intraductal papillary neoplasms of the
bile duct (IPNBs)], are frequently associated with more wide-
spread atypia, and should prompt the complete examination of
the remainder of the gallbladder.
Consensus statements
• Particularly in areas of high incidence, routine gallbladder
specimens should be pathologically assessed and the mini-
mum examination should include the microscopic evalua-
tion of three sections and the cystic duct margin.
• During the initial analysis, a finding of high-grade dysplasia,
hyalinizing cholecystitis and/or neoplastic polyps should
prompt the complete sampling of the entire gallbladder speci-
men to accurately stage any associated invasive malignancy.
• Gallbladder specimens with proven cancer should be exten-
sively sampled and prognostic factors determined, including
microscopic depth of tumour invasion, tumour involvement
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of the cystic duct margin, involvement of Rokitansky–
Aschoff sinuses, and serosal versus hepatic surface involve-
ment.
• Provided the patient is medically fit for surgery, data sup-
port the resection of all gallbladder polyps of >1.0 cm in
diameter and those with imaging evidence of vascular stalks.
Evaluation and management of a gallbladder
mass
Gallbladder cancer is an aggressive malignancy with poor prog-
nosis. Only 25% of patients will undergo potentially curative
surgery, and just 16% will survive for more than 5 years. Sur-
gical treatment has proven to be curative in some patients, but
postoperative survival is so closely associated with pathologic
tumour stage that resectional surgery has as much of a role as
a staging modality as it does as a therapeutic endeavour.
Because GBC is relatively uncommon, multiple longitudinal
studies have included GBC along with other bile duct malig-
nancies, such as cholangiocarcinoma. However, current evi-
dence shows that surgical approaches, margin-free resection
rates and longterm survival differ completely between these
types of tumour. Therefore, GBC must be considered and trea-
ted as a separate entity.
This section focuses on current controversies in the manage-
ment of the specific group of patients who present with preop-
erative suspicion for or a confirmed diagnosis of GBC and an
intact gallbladder.
Accurate staging to predict technical and oncologic
resectability
Patients who present with symptoms of indigestion, pain,
weight loss and/or jaundice may be discovered to have a gall-
bladder mass via ultrasound study or cross-sectional imaging.
Alternatively, gallbladder pathology may be incidentally identi-
fied during the work-up of other symptoms. Once identified,
gallbladder masses are best evaluated by contrast-enhanced
abdominal computed tomography (CT) because the additional
capacity of this modality to interrogate portal nodes, peritoneal
implants and vascular invasion makes it the most accurate
modality with which to determine resectability.19 The diagnos-
tic and staging accuracy of CT may be augmented by gadolin-
ium-enhanced magnetic resonance imaging (MRI), which can
provide more detailed evaluation of the common hepatic duct
(CHD) /common bile duct (CBD) and liver parenchyma, espe-
cially in patients with concomitant liver steatosis or cirrhosis.
The presence of lymph node (LN) metastases in GBC is often
difficult to determine preoperatively; abdominal CT and MRI
are reported to facilitate a detection rate of 24%.20 If imaging
identifies suspicious intrahepatic masses, regional lymphade-
nopathy and/or peritoneal implants, endoscopic, percutaneous
or laparoscopic biopsy should be performed prior to resection.
In patients with known or suspected GBC, 18-FDG positron
emission tomography (PET)-CT has demonstrated the ability
to detect occult peritoneal, omental and/or LN metastases with
sensitivity of 56%.21 This may be relevant in patients in whom
GBC is discovered incidentally because the detection of clini-
cally occult metastasis may help identify those patients who
would not benefit from a radical resection prior to laparot-
omy.22
Influence of jaundice on surgical decision making
The majority of GBC patients who present with jaundice will
have disseminated disease even if it is not detectable on preop-
erative work-up or operative exploration. The en bloc resection
of the CHD/CBD, which is frequently required in these
patients, is difficult and associated with positive (R1) margin
status in 40% of patients.23,24 Despite anecdotal reports of
longer postoperative survival in GBC patients presenting with
the rare combination of jaundice without nodal involvement,25
even in patients with a negative (R0) margin, the median
length of disease-free survival in preoperatively jaundiced
patients is only 6 months.26 Based on these data, preoperative
jaundice should be considered a relative contraindication to
radical resection of GBC.
Surgical management of the gallbladder mass
Following adequate staging to rule out distant metastases, un-
resectable regional nodal disease, and/or local advancement to
critical hepatic vascular/biliary structures, medically fit patients
should be considered for surgical exploration. The intraopera-
tive decision making involves several key elements.
Patients without a tissue diagnosis
In many instances, there is suspicion of GBC but no tissue
diagnosis prior to exploration. Although preoperative imaging
can help to differentiate GBC from other benign aetiologies,
such as acute and/or chronic cholecystitis, mass-forming xan-
thogranulomatous cholecystitis is known to masquerade as
GBC.27 In the absence of a preoperative diagnosis, extensive in-
traoperative core needle biopsy with immediate frozen-section
analysis is recommended prior to committing to radical resec-
tion. In the frequent presentation of xanthogranulomatous
cholecystitis associated with large gallstones and extensive
inflammation that limits the ability to perform simple chole-
cystectomy, cholecystotomy with stone removal is recom-
mended only after intraoperative biopsies have proved negative
for malignancy.27,28
Role of staging laparoscopy
Given the propensity of GBC to involve regional nodes and
peritoneal surfaces,29 staging laparoscopy can help to prevent
unnecessary surgical exploration in 38–62% of patients.30 Up
to 23% of cases can be determined to be oncologically unresec-
table with simple laparoscopy. The addition of laparoscopic
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ultrasound and interaortocaval LN frozen-section evaluation
can potentially further increase the detection rate in patients
who will not benefit from radical resection.31 Based on the
high incidence of positive findings, staging laparoscopy is rec-
ommended prior to laparotomy for all instances of suspected
or proven GBC.
Intraoperative LN evaluation
Gallbladder cancer most commonly spreads from the gall-
bladder to the periportal LNs and then to the aortocaval
station, but may also cross to the coeliac nodal station
before advancing to more distant axial sites. Longterm sur-
vival has been reported in patients with involvement of the
pancreaticoduodenal and hepatic artery LNs (N1). By con-
trast, no survival benefit is evident in those with involved
para-aortic, coeliac or superior mesenteric artery (SMA)
nodes (N2).32,33
Data from high-volume centres demonstrating that up to
26% of GBC patients will have axial LN involvement (aorto-
caval/coeliac) that would negate any benefit of radical surgery
indicate that aortocaval LN sampling should be performed
routinely at the initiation of the operation.32,33 Although peri-
portal regional LN (N1) involvement does not contraindicate
radical resection, it is a very poor prognostic indicator, and
therefore the presence of an institutional neoadjuvant therapy
protocol for locally advanced GBC may indicate that patho-
logic confirmation of regional disease should discontinue the
immediate plan for up-front resection in favour of the pro-
spective evaluation of pre-resection chemotherapy and/or
chemoradiotherapies.34
Laparoscopic and open approaches to definitive
resection
Minimally invasive resection of intact GBC has been performed
at specialized expert centres. These centres have reported safety
and feasibility outcome data for T1b, T2 and even T3 tumours
that rival the outcomes of open surgery,35 but no randomized
studies have objectively compared the minimally invasive and
open surgery approaches. Oncologic adequacy data on LN
sampling and surgical/hepatic parenchymal margins are preli-
minary and incomplete. Given the current data, minimally
invasive surgery in oncologic GBC resection is not the standard
of care and its use should be limited to specialized centres that
have demonstrated the ability to overcome the technical chal-
lenges associated with: (i) adequate portal and aortocaval LN
sampling; (ii) R0 liver transection margins, and (iii) CHD/
CBD resection or reconstruction.35
Extent of primary resection
After evaluation for peritoneal and regional nodal disease,
patients with tumours limited to the wall of the gallbladder
(T1b–2) are recommended to undergo radical cholecystectomy
with en bloc resection of adjacent liver parenchyma. In these
instances, CHD/CBD resection can be reserved for gross
involvement by direct contact or microscopic involvement of
the intraoperatively evaluated cystic duct margin.24 Regardless
of final margin status, bile duct involvement by GBC portends
a poor prognosis, probably because it is frequently associated
with regional lymphatic invasion.23
Management of locally advanced GBC with adjacent
organ involvement
For T3 or T4 tumours, the extent of the primary resection
is debatable. As direct invasion of adjacent organs that nor-
mally contact the gallbladder (duodenum or colon) does not
necessarily indicate nodal involvement and is denoted as T3
in the staging system, en bloc adjacent organ resection is
permissible but has not been associated with improved long-
term survival.24 Likewise, longterm survival after radical
resections that included major hepatectomy, CHD/CBD and/
or vascular resection or reconstruction has been anecdotally
reported,24,36 but these radical resections have not been asso-
ciated with longer disease-free or overall survival on a popu-
lation basis. Instead, they are associated with increased
morbidity and mortality. Radical resections of locally
advanced primary tumours should, therefore, be performed
only in medically fit patients after multidisciplinary discus-
sion. Although R0 resection for GBC is associated with
longer survival, tumour biology and stage, rather than the
extent of resection, are the most important predictors of sur-
vival after surgery.23,37
Extent of lymphadenectomy
Positive regional LNs are predictors of worse survival in GBC.
By incorporating the biology of disease (positive LN) and the
quality of lymphadenectomy (total LN count), the LN ratio
has been shown to be an important predictor of survival after
surgery.38 Based on these data, adequate staging requires the
retrieval of a minimum of six nodes.39 To achieve this, dissec-
tion beyond the immediate portal nodes is frequently
required.
Postoperative follow-up
Few published studies have focused on the patterns and timing
of recurrence after resection of GBC, but up to 50% of
resected patients fail within 2 years of surgery, typically with a
combination of regional and distant recurrence.33 As such, sur-
veillance follow-up of asymptomatic post-resection patients
who are not treated with adjuvant therapy is probably best
accomplished with chest/abdomen/pelvis CT at intervals of
3–4 months.
Consensus statements
• The minimum staging evaluation of patients with suspected
or proven GBC includes contrasted cross-sectional imaging
and diagnostic laparoscopy.
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• Adequate lymphadenectomy includes intraoperative assess-
ment of any suspicious regional nodes, evaluation of the
aortocaval nodal basin, and the recovery of at least six
nodes. Patients with confirmed metastases to N2 nodal
stations do not benefit from radical resection and should
receive systemic and/or palliative treatments.
• Primary resection of patients with early T-stage (T1b–2) dis-
ease should include en bloc resection of adjacent liver
parenchyma. Resection of the CHD/CBD is only beneficial
or required in cases of gross direct extension or microscopic
involvement of the cystic duct margin.
• In patients with locally advanced primary tumours, and par-
ticularly in those with jaundice, the risk : benefit ratio of
radical surgery, to include major hepatectomy, vascular and/
or adjacent organ resection, is marginal and these methods
should only be considered in expert centres after multidisci-
plinary discussion.
• Minimally invasive GBC resections should be limited to
early T-stage patients treated by expert surgeons who have
demonstrated outcomes using this approach that are onco-
logically equivalent to those of open surgery.
Evaluation and management of incidentally
discovered GBC
After an incidental GBC is discovered after cholecystectomy,
the rationale for re-resection is based on the incidence of resid-
ual disease, the ability of additional staging information to
prognosticate survival and to direct adjuvant therapy, and
whether re-resection improves patient outcomes.
Incidence of residual disease
The incidence of residual disease varies by the T-stage classifi-
cation of the primary tumour. The incidence of finding resid-
ual disease at any site can be as high as 37.5% in T1 tumours,
56.7% in T2 tumours, and 77.3% in T3 tumours.40 Incidences
of residual disease in the liver bed and/or LNs are lower, rang-
ing from 12% in patients with T1 tumours to 46% in those
with T3 tumours.40 A collaborative group study involving 21
European centres reported the incidence of residual disease to
be as high as 82% in patients with T2–3 tumours,41 and an
experience from Chile yielded a similar rate of 72% for the
finding of residual disease at re-exploration.42
Re-resection and survival outcomes
In the absence of prospective clinical trials, observational stud-
ies indicate that complete resection of residual disease is associ-
ated with improved survival. The European collaboration
(French Association of Surgery – Gallbladder Cancer) [AFC–
GBC] reported a 5-year survival rate of 41% in patients who
underwent re-resection compared with only 15% in those who
did not.41 The survival advantage of a complete R0 resection,
independent of the presence of residual disease at
re-exploration, has also been demonstrated.42 More recently,
the University of Toronto reported improved survival in
patients in whom curative resection was performed, thus
supporting re-resection.43 When assessed separately by T-stage
classification, re-resection has been associated with improved
survival in both T2 and T3 tumours.41,44
Whereas most authors agree that T1a tumours are ade-
quately treated with cholecystectomy alone, re-resection of T1b
tumours is more controversial. A decision-analytic Markov
model performed specifically for T1b tumours suggests that
re-resection is associated with improved 5-year survival (87.5%
versus 61.3%), and that the number of years gained was great-
est in younger patients, regardless of gender.45 A recent study
using the National Cancer Institute’s Surveillance, Epidemiol-
ogy, and End Results (SEER) database demonstrated a similar
finding in that radical resection was associated with improved
survival in patients with T1b tumours but not in those with
T1a tumours.46 Thus, re-resection is indicated for T1b, T2 and
T3 incidentally discovered GBCs.
Preoperative evaluation: the role of PET
Although it is standard practice to obtain high-quality cross-
sectional imaging in the form of CT or MRI, the utility of
PET in this setting is unknown. A group from the Memorial
Sloan–Kettering Cancer Center (MSKCC) reported that, when
assessing patients with incidental GBC, PET scans altered
management in only 13% of patients.47 Although Shukla et al.
reported on their experience using PET prior to re-resection,
it is not clear how frequently PET detected disease that was
missed on multi-detector CT in M1 patients.48 Furthermore,
analysis that determined that PET can correctly identify 33%
of patients to have inoperable disease that was missed on CT
was conducted in only three patients.48 A group from Chile
reported that PET-CT altered management in 38% of patients;
however, patients did not undergo CT or MRI alone and
hence it was not possible to surmise the unique contribution
of PET to the improved detection of disease.22 Thus, the role
of PET prior to re-resection surgery remains undetermined,
but it is likely that PET should be selectively utilized only
when questionable or concerning features are apparent on CT
or MRI.
Operative strategy
Staging laparoscopy
Prior to performing laparotomy at the time of re-resection, a
staging laparoscopy may be performed. Goere et al. examined
the utility of this approach in a mixed cohort of patients with
biliary cancer and found it to give the highest yield (37%
determined to be unresectable) in patients with GBC.30 How-
ever, this study did not include patients with incidentally
discovered GBC, but instead referred to those in whom a gall-
bladder mass was apparent on preoperative imaging. Focusing
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only on patients presenting with incidental GBC, the group
from MSKCC found that of patients who underwent staging
laparoscopy prior to laparotomy, 20% of patients with distant
disease were identified with laparoscopic evaluation. Predictors
of a positive laparoscopy included T3 disease, a poorly differ-
entiated tumour and a positive margin at the time of original
cholecystectomy.49 Thus, it seems that the yield of staging
laparoscopy is probably highest when the technique is per-
formed selectively, using adverse pathologic characteristics such
as T3 disease, poor differentiation and positive margin status
to guide selection.
Port site resection
In an attempt to lower the rate of wound recurrence, some
authors have advocated the use of port site resection at the
time of re-resection in view of the possibility of tumour
contamination at the time of laparoscopic cholecystectomy.
However, this practice is not supported by the literature. Fuks
et al. reported that only one of 54 patients who underwent
port site resection was found to have disease, and that this
patient developed and died from generalized peritoneal disease
soon afterwards.41 Port site resection was not associated with
improved survival and was associated with a 15% incisional
hernia rate.41 Maker et al. reported a similar finding at
MSKCC, where port site disease was associated with the
development of generalized peritoneal disease and port site
resection was not associated with improved survival.50 Thus,
routine port site resection is not indicated.
Lymph node dissection
The incidence of LN involvement varies by T-stage, approxi-
mating 12%, 31% and 45% in patients with T1b, T2 and T3
tumours, respectively.40 In a 2009 SEER study, lymphadenec-
tomy in conjunction with radical resection was associated
with improved survival in comparison with radical resection
alone in patients with T1b and T2 tumours.51 Others have
shown that excision of at least five LNs was associated with
improved survival compared with a lesser LN yield.52 These
and other data have led to the recommendation that six LNs
should be removed for accurate staging.39 However, the med-
ian LN yield reported in most studies is only two or three,
which indicates the need for improvement in this area.
Biopsy of N2 level nodes may provide prognostic benefit and
may be used to tailor surgical approaches; however, formal
LN dissection should be limited to the hepatoduodenal liga-
ment, as extended LN excision (i.e. coeliac or para-aortic) is
not associated with improved outcomes because the involve-
ment of these distant nodes represents distant metastatic
disease.53
Extent of liver resection
The goal of the liver resection is to obtain an R0 resection.40
The routine performance of a major hepatectomy compared
with a partial hepatectomy (non-anatomic resection of the gall-
bladder bed) or a formal segment IVb/V resection has not been
associated with improved survival, but has been linked to
increased morbidity.24 This has been demonstrated repeatedly
in multiple studies41,42,52 and the trend over time has favoured
the performance of a lesser resection, as long as negative
margins are achieved.
Bile duct resection
Similarly to major hepatectomy, routine bile duct resection has
been shown repeatedly to have no impact on survival, but,
rather, to increase morbidity.24,40,44 Furthermore, bile duct
resection has not been associated with a higher LN yield.40
Thus, bile duct resection should not be routinely performed. It
may be indicated by a positive cystic duct margin at cholecys-
tectomy or when it is necessary to achieve an oncologically
sound re-resection with a negative margin. Allowing sufficient
time for the resolution of portal inflammation following chole-
cystectomy aids in the identification and preservation of biliary
structures.
Consensus statements
• Patients with incidentally identified T1b, T2 or T3 disease
in a cholecystectomy specimen should undergo re-resection
unless this is contraindicated by advanced disease or poor
performance status.
• Prior to re-resection, patients should undergo high-quality
cross-sectional imaging with CT or MRI; PET should be
used selectively to clarify features of concern identified on
CT or MRI.
• Staging laparoscopy should be considered prior to laparot-
omy, particularly in patients with T3 tumours and adverse
pathologic characteristics. Routine port site excision is not
indicated.
• Re-resection should include portal lymphadenectomy and
excision of all LNs in the hepatoduodenal ligament.
Extended LN dissection is not routinely indicated.
• The goal of re-resection is an R0 resection. Major hepatec-
tomy and/or bile duct resection is not routinely indicated
unless these are required to achieve an R0 margin.
Advances in neoadjuvant and adjuvant
chemotherapy and radiation approaches to
GBC
Gallbladder cancer epidemiology and prognosis
Annually, GBC affects over 140 000 patients worldwide and
over 100 000 will die each year from this aggressive disease.54
Women are affected more often than men, and in the USA the
Hispanic population and Alaskan natives have disproportion-
ately high incidences of this disease.55 Most patients are diag-
nosed at an advanced stage of disease, in which the 5-year
survival rate is <10%. Surgical resection in early-stage disease
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offers potential cure, but only a minority of patients (10%) are
candidates for these procedures, which further contributes to
the overall poor level of survival in this disease.56
Role of adjuvant systemic chemotherapy after GBC
resection
Because there is a paucity of Level I evidence provided by ran-
domized Phase III clinical trials, adjuvant therapy guidelines
for this disease are based on retrospective data analyses and
expert opinion. A review of the SEER database indicates that
adjuvant chemoradiation improved survival in patients with
regionally advanced disease (with lymphatic or hepatic involve-
ment).57 One randomized Phase III study of adjuvant chemo-
therapy, conducted in Japan in GBC patients, demonstrated
improved survival with adjuvant 5-fluorouracil and mitomy-
cin.58 A recent literature-based meta-analysis of biliary cancer
patients receiving adjuvant therapy reported a non-significant
improvement in survival in biliary cancer patients (including a
large number of patients with GBC) treated with adjuvant
therapy in comparison with those treated with surgery alone.59
However, in a subset analysis the authors concluded that surgi-
cally resected patients with positive LNs or R1 resection mar-
gins derived the most benefit from adjuvant chemoradiation or
chemotherapy.59
These retrospective data are limited by the fact that most of
the patients included did not undergo extended surgery for
their disease and therefore the true benefit of adjuvant therapy
in patients with stage T1b–2 disease post-radical cholecystec-
tomy is as yet unknown. However, a retrospective study con-
ducted at the Mayo Clinic, in which most patients underwent
extended oncologic resection, did record statistically superior
survival with adjuvant chemoradiation.60 Based on these obser-
vations, it is reasonable to recommend adjuvant therapy for
patients with stage II or higher GBC following surgical resec-
tion. The range of chemotherapy includes gemcitabine, fluoro-
pyrimidines or gemcitabine-based combination chemotherapy.
In combination, these data suggest that adjuvant therapy
may improve survival in patients with high-risk (T3–4, N1–2,
positive margin) pathologic features. With reference to patients
with node-positive disease, resected with negative margins,
there is insufficient evidence at the current time to choose
between adjuvant chemotherapy and chemoradiation. Although
the SEER data support the use of adjuvant chemoradiation
over chemotherapy alone, there is insufficient record of che-
motherapy usage in the SEER database.61 Furthermore, the
majority of patients included in this database underwent less
than optimal surgical resections and therefore the precise bene-
fit of adjuvant chemotherapy after margin-negative radical
resection is undefined at this time. In the absence of clear evi-
dence, many experts will treat node-positive, margin-negative
patients with adjuvant chemotherapy followed by consolidative
chemoradiotherapy after restaging confirms an absence of
distant metastases. Adjuvant chemoradiation is the treatment
of choice in patients with R1/2 resection margins.
Role of neoadjuvant therapy in localized GBC
The role of neoadjuvant therapy in localized GBC deserves fur-
ther exploration. One small study from Chile concluded that
neoadjuvant therapy conferred no therapeutic advantage. How-
ever, this study predated the advent of gemcitabine-based com-
bination regimens for biliary cancer.62 Moreover, the
application of regional radiotherapy in non-surgically staged
patients, many of whom will be found to have peritoneal or
nodal disease outwith radiation portals, is not ideal. Based on
the lack of data on this topic, the aggressive nature of the dis-
ease, and the morbidity of radical surgery, neoadjuvant therapy
would be best applied to patients with clinical T3/T4/N1 dis-
ease on clinical trial or registry. As the Advanced Biliary Can-
cers (ABC)-02 trial proved that gemcitabine and cisplatin
chemotherapy facilitates disease control in 80% of patients, this
is currently the best regimen to apply appropriately in the neo-
adjuvant setting.63
Treatment of patients with locally advanced and
unresectable GBC
Patients with locally advanced and unresectable GBC face a dis-
mal prognosis and suffer from morbidity resulting from biliary
obstruction, pain, cachexia and infections. In this subset of
patients, critical palliative manoeuvres include the maintenance
of adequate biliary drainage via percutaneous or endoscopic
stenting, nutritional support, pain control and management of
gastroparesis. Systemic agents remain the mainstay of therapy,
with gemcitabine–cisplatin chemotherapy being the treatment of
choice in patients with good performance status [Eastern Coop-
erative Oncology Group (ECOG) status: 0–1], and single-agent
gemcitabine in patients with ECOG performance status of 2.
Patients with advanced GBC included in the ABC-02 trial
derived significant benefit from the gemcitabine–cisplatin regi-
men. In patients with advanced GBC, acceptable alternative
systemic therapeutic options include gemcitabine plus capecita-
bine.64–66
Future genetic and targeted therapy
The use of targeted therapeutics represents a promising strat-
egy for advanced GBC. Recent genomic sequencing studies
have identified a host of genetic aberrations that are potentially
targetable. These include ERBB2 amplifications, mutations or
amplifications of the PI3-kinase family genes, FGFR mutations
or fusions and aberrations of the chromatin modulating
genes.67,68 Epidermal growth factor receptor (EGFR) inhibitors
like erlotinib and cetuximab have been investigated in the
Phase II setting in this disease with encouraging results, but
confirmatory studies are awaited before standard-of-care rec-
ommendations can be entered.69,70
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Consensus statements
• Given their generally poor postoperative prognosis and ele-
vated surgical morbidity, patients with preoperatively staged
T3–4 N1 disease should be considered for clinical trials
studying the efficacy of neoadjuvant chemotherapy.
• Following R0 resection of stage T2 and higher N1 GBC,
patients should be considered for adjuvant systemic chemo-
therapy and/or chemoradiotherapy.
• Patients with resected GBC with positive margins should be
considered for adjuvant chemoradiation therapy.
• In patients with unresectable locally advanced and N2-posi-
tive GBC, systemic chemotherapy with gemcitabine doublets
can provide effective palliation and prolong survival.
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